$ Research digest // secretagogue comparisons
Sermorelin is GHRH(1-29), the native short-acting fragment — read here against the other GH secretagogues.
A green-on-black readout of what the studies measured: the GHRH-receptor mechanism, the ~10-12 minute half-life that motivated the longer-acting analogues, and how sermorelin stands beside ipamorelin, CJC-1295, and tesamorelin. Every quantitative claim cited.
The short version
Sermorelin is a synthetic copy of the first 29 building blocks of GHRH — the brain's own "make growth hormone" signal. It tells the pituitary (the small gland that releases growth hormone) to release the body's own growth hormone in natural bursts, rather than supplying that hormone from outside. It was once an approved prescription drug for children who were not growing, was pulled from the US market in 2008 for business reasons, and is now made by compounding pharmacies. This site reads the published research and sets sermorelin beside the peptides it is most often confused with.
What sermorelin is
Sermorelin is the 1-29 N-terminal fragment of growth hormone-releasing hormone (GHRH) — the shortest fragment of the 44-amino-acid hormone that still keeps full activity at the GHRH receptor [15]. It is a pituitary GH secretagogue (a substance that tells a gland to release its hormone): it binds receptors on the anterior pituitary and prompts the gland to release the body's own growth hormone (GH) in its natural pulses, which in turn raises IGF-1 (a growth signal the liver makes when GH rises) [4].
That upstream position is the whole point of the molecule. Because sermorelin acts on the pituitary rather than supplying GH directly, the body's own brakes — somatostatin and IGF-1 feedback — stay intact, so the natural pulsatile (released in bursts, not a steady drip) pattern of GH release is preserved [4]. An editorial in Clinical Interventions in Aging argued that this makes sermorelin a more physiologic approach to adult-onset GH insufficiency than recombinant GH, which floods the system with hormone from outside [4].
The regulatory history is frequently misstated, so state it plainly: sermorelin was an FDA-approved prescription drug for evaluating and treating growth hormone deficiency and short stature in children, and it was withdrawn from the US market in 2008 for commercial reasons — not for any problem with safety or efficacy. It is not a currently-marketed FDA-approved finished drug; it is now prepared by compounding pharmacies and is treated as a long-standing Category 1 bulk drug substance under the FDA's Section 503A framework (final guidance January 2025). The research-grade sermorelin discussed on this site is supplied for laboratory research, not as a medicine to self-administer.
Sermorelin Peptide: GHRH(1-29) at a Glance
As a sermorelin peptide, GHRH(1-29) is a 29-residue amidated chain with a molecular weight near 3,358 Da (CAS 86168-78-7). It is a member of the GHRH-analogue class — distinct from the GHRP/secretagogue class (ipamorelin, GHRP-2, GHRP-6) that works through a separate receptor entirely [15].
The peptide's defining feature is brevity. Native GHRH(1-29) clears from plasma in roughly 10-12 minutes, yet a single intravenous dose keeps serum GH elevated for about 3 hours [3]. That short half-life is the engineering motivation for the longer-acting analogues — the D-Ala2 substitution and the Drug Affinity Complex (DAC) behind CJC-1295, and the stabilized analogue tesamorelin. The comparison digest on this site is built around exactly that contrast: see sermorelin vs ipamorelin and sermorelin vs CJC-1295.
What does sermorelin do to the body?
It binds GHRH receptors on anterior-pituitary somatotrophs (the GH-producing cells), activating the cAMP/PKA pathway to stimulate synthesis and pulsatile release of the body's own growth hormone, which in turn raises hepatic IGF-1 — all while somatostatin and IGF-1 negative feedback remain intact [4][15]. The full receptor cascade is laid out in how sermorelin works at the GHRH receptor.
What that produced in studies depends on who was studied. In prepubertal GH-deficient children, once-daily subcutaneous GHRH(1-29) accelerated linear growth, raising first-year height velocity from about 4.1 cm/year to roughly 7-8 cm/year without excessive IGF-1 generation [1]. In healthy older men, 0.5 mg and 1 mg twice daily for 14 days produced dose-related increases in 24-hour GH and IGF-1; at the high dose, those parameters no longer differed from those of young men [2]. The body-composition and anti-aging marketing has run well ahead of this evidence — a distinction this site keeps in plain view. The tolerability record, including the sermorelin side effects reported in studies, is summarized on the research page.
What is sermorelin used for?
Historically, sermorelin was FDA-approved to evaluate and treat idiopathic growth hormone deficiency and short stature in children, where once-daily subcutaneous dosing accelerated linear growth [1]. It was also used diagnostically — as a GH stimulation test, a single dose given to probe the pituitary's capacity to release growth hormone.
Beyond pediatrics, GHRH(1-29) and its stabilized analogues have been studied in adult GH-axis research: aging, body composition, cognition, and sleep [2][6]. Authorities have been explicit that this last category is not settled — an Annals of Internal Medicine editorial judged GH-secretagogue use for the effects of aging "not yet ready for prime time" [5]. For the full set of frequently asked questions about sermorelin, the studied doses in sermorelin dosage in the research literature, and the sermorelin references and citations behind every figure, follow the links; nothing here is a dosing instruction.